Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Edwards Lifesciences Corp. pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Solvency Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Edwards Lifesciences Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Edwards Lifesciences Corp., profitability ratios (quarterly data)
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
- Gross profit margin
- The gross profit margin demonstrated consistent stability and a slight upward trend over the analyzed periods. Starting from approximately 74.52% in March 2017, the margin remained relatively flat, with minor fluctuations around the mid-70s. The data indicates a steady ability to manage production costs relative to revenue throughout the timeframe, culminating in a high of 76.13% by the end of 2021.
- Operating profit margin
- The operating profit margin exhibited more variability in comparison to the gross profit margin. Initially, it remained around 30-32% up to the end of 2017 but experienced a significant decline to approximately 20% in 2018 and 2019. Thereafter, an improvement occurred, with margins rising gradually from 26.38% at the start of 2020 to stabilize above 32% in the final quarters of 2021. This pattern suggests temporary operational challenges during 2018-2019 followed by successful margin recovery through improved cost control or revenue enhancement measures.
- Net profit margin
- Net profit margins followed a broadly cyclical pattern reflecting operating performance and possibly other financial factors such as taxes or non-operating expenses. Margins were around 17% in early 2017, increased to near 20% by late 2018 and early 2019, then rose sharply in 2020 to exceed 24%. This was followed by a decline in late 2020 but a strong rebound in 2021, peaking at nearly 30% before a slight decrease at year end. Overall, net profitability showed an upward trajectory with periods of volatility likely tied to varying expense or tax considerations.
- Return on equity (ROE)
- ROE showed a generally positive trend with some fluctuations. Initially close to 20% in early 2017, it experienced a dip to approximately 17% in mid-2017, before recovering to above 23% by early 2019. Despite a decline during 2020, the ROE increased again in 2021 to a peak near 28.5%, indicating effective utilization of shareholder equity to generate profits, despite intermittent declines possibly due to shifting earnings or equity base.
- Return on assets (ROA)
- ROA closely tracked net profit margin movements, demonstrating steady improvement over the period. Starting at roughly 10.25% in early 2017, it increased gradually, reaching a high of over 18% by late 2020 and sustained this elevated level through 2021, peaking at 19.09%. This indicates enhanced efficiency in asset utilization to generate earnings, with particularly strong performance maintained in the final years covered by the data.
Return on Sales
Return on Investment
Gross Profit Margin
Edwards Lifesciences Corp., gross profit margin calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Gross profit margin = 100
× (Gross profitQ4 2021
+ Gross profitQ3 2021
+ Gross profitQ2 2021
+ Gross profitQ1 2021)
÷ (Net salesQ4 2021
+ Net salesQ3 2021
+ Net salesQ2 2021
+ Net salesQ1 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The quarterly financial data presents several key observations regarding the company's sales and profitability trends over the specified periods.
- Net Sales
- Net sales show a general upward trend from the beginning of 2017 through the end of 2021, increasing from approximately $883.5 million in Q1 2017 to around $1.33 billion in Q4 2021. There are slight fluctuations within this period, including a notable dip in mid-2020 where sales decreased to $925 million in Q2 2020 from $1.13 billion in Q1 2020, likely reflecting external disruptions. Following this decline, net sales recovered strongly and continued their growth trajectory into 2021, reaching the highest levels in the dataset.
- Gross Profit
- Gross profit values also exhibit an overall growth pattern consistent with net sales. Starting at about $668 million in Q1 2017, gross profit peaked at approximately $1.02 billion in Q4 2021. A temporary decline is evident in Q2 2020, where gross profit fell to roughly $687 million from $864 million in the prior quarter, mirroring the net sales dip. After this trough, gross profit rebounded and steadily increased, maintaining higher levels toward the end of the analysis period.
- Gross Profit Margin
- Gross profit margin remained relatively stable throughout the periods analyzed, consistently within a range of approximately 74.0% to 76.1%. The margin generally fluctuates around 75%, indicating consistent profitability in relation to sales despite changes in absolute sales and gross profit figures. There is a slight upward trend visible toward the end of 2021, with the margin reaching over 76%, suggesting improved efficiency or cost management in gross profit generation.
In summary, the data demonstrates strong revenue growth over the five-year span with a temporary contraction around mid-2020, potentially related to external market conditions. Gross profit trends mirror sales activity, maintaining a healthy profit margin that shows modest improvement by the end of 2021. These patterns suggest resilience and effective cost control, contributing to increasing profitability on higher sales volumes.
Operating Profit Margin
Edwards Lifesciences Corp., operating profit margin calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Operating income (loss) | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Operating profit margin = 100
× (Operating income (loss)Q4 2021
+ Operating income (loss)Q3 2021
+ Operating income (loss)Q2 2021
+ Operating income (loss)Q1 2021)
÷ (Net salesQ4 2021
+ Net salesQ3 2021
+ Net salesQ2 2021
+ Net salesQ1 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The data presents the quarterly financial performance for an unspecified entity, reflecting trends over five years from March 2017 to December 2021. Key financial indicators include operating income (loss), net sales, and operating profit margin.
- Operating Income (Loss)
-
The operating income exhibits notable fluctuations throughout the periods. Initially, it was relatively strong, peaking at $342.2 million in December 2017. However, a significant decline occurred in December 2018, showing a loss of $5.3 million, interrupting an otherwise positive trend. The figure rebounded subsequently, reaching highs above $350 million in 2020 and 2021, with the highest recorded in June 2021 at approximately $542.1 million. Apart from the exception in mid-2020, where a sharp loss of $169.7 million was recorded, operating income generally trended upward, indicating intermittent but strong profitability.
- Net Sales
-
Net sales display a steady upward trajectory over the five-year span. Starting at approximately $883.5 million in March 2017, sales grew consistently, with minor variations, to peak near $1.38 billion in December 2021. Noteworthy is a dip in mid-2020, coinciding with the period of operating income loss, where sales fell to $925 million in June 2020 from $1.13 billion in March 2020. Following this, sales quickly recovered and then increased to reach new highs by the end of the observed period, reflecting a resilience and strong market demand.
- Operating Profit Margin
-
The operating profit margin data, available from December 2017 onwards, complements the observations on operating income and sales. The margin consistently hovered around 20%-30% before the disruption in 2020. A sharp decline to around 18% in mid-2020 coincides with the negative operating income. Post-2020, the margin improved markedly, surpassing 32% in 2021, with a peak margin of approximately 33.19% in December 2021. This improvement signals enhanced operational efficiency or profitability post-challenge period.
Overall, the financial data reveals strong growth in net sales accompanied by fluctuating operating income and profit margins, highlighting periods of operational challenges followed by robust recovery and improvement. The mid-2020 downturn appears as an outlier, with swift correction and subsequent growth in both profitability and sales, indicating effective management response and favorable market conditions in later quarters.
Net Profit Margin
Edwards Lifesciences Corp., net profit margin calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Net profit margin = 100
× (Net income (loss)Q4 2021
+ Net income (loss)Q3 2021
+ Net income (loss)Q2 2021
+ Net income (loss)Q1 2021)
÷ (Net salesQ4 2021
+ Net salesQ3 2021
+ Net salesQ2 2021
+ Net salesQ1 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data displays notable fluctuations and trends in net income, net sales, and net profit margin over the observed quarterly periods.
- Net Income (Loss)
- Net income shows considerable variability across quarters. Initial quarters in 2017 exhibit generally positive net income values, peaking at 282,700 thousand US dollars in June 2018. However, a pronounced dip is observed in December 2017 with a net loss of 2,800 thousand US dollars. The year 2020 presents a mix of recovery and setbacks, where despite an overall upward trend, the second quarter of 2020 shows a significant negative swing to -121,900 thousand US dollars. Post this period, net income rebounds strongly, reaching a high of 489,500 thousand US dollars in December 2021, indicating improved profitability in the latter part of the dataset.
- Net Sales
- Net sales consistently increase over time with some fluctuations, evidencing general growth in revenue generation. Beginning at 883,500 thousand US dollars in March 2017, sales rise steadily, reaching a peak of 1,376,000 thousand US dollars in December 2021. Some temporary decreases are present, notably in the mid-2020 period where sales dropped from 1,128,700 thousand to 925,000 thousand US dollars, likely reflecting an external influence impacting sales performance. Despite such dips, the overall trajectory remains positive.
- Net Profit Margin
- This metric, calculated only from March 2018 onward, indicates profitability as a percentage of net sales. The margin remains relatively stable within a mid-to-high teens range initially, fluctuating between approximately 16.25% and 20.03% through 2019. A sharp increase is observed starting in December 2019 with margins exceeding 24%, then a decline during mid-2020 corresponding to the period of negative net income. From late 2020 onward, net profit margins steadily improve and reach an exceptional level, peaking at 29.69% in December 2021. This suggests improved operational efficiency or pricing power during the recent quarters.
In summary, the data reveals overall financial growth and strengthening profitability despite intermittent periods of volatility. Net sales growth underpins expanding business volume, while net income fluctuations suggest varying expense or cost influences. The increase in net profit margin, especially in the latest quarters, points to enhanced financial management or market conditions favoring profit generation.
Return on Equity (ROE)
Edwards Lifesciences Corp., ROE calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
ROE = 100
× (Net income (loss)Q4 2021
+ Net income (loss)Q3 2021
+ Net income (loss)Q2 2021
+ Net income (loss)Q1 2021)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends in profitability, equity, and return on equity (ROE) over the observed periods.
- Net Income (Loss)
- The net income values exhibit significant volatility over the quarters. Initially, net income starts at 230,200 thousand US$ at the end of March 2017, and experiences a declining trend through the end of 2017, including a notable loss of 2,800 thousand US$ in December 2017. From 2018 onward, the company demonstrates periodic recovery and growth in net income, reaching a quarterly peak of 338,200 thousand US$ in September 2021. However, a substantial loss is recorded in June 2020 at -121,900 thousand US$, interrupting the growth trend. Despite this, the net income quickly rebounds in subsequent quarters, returning to positive margins and increasing substantially by the end of the data series.
- Stockholders’ Equity
- Stockholders’ equity shows a generally steady upward trend across the periods, growing from 2,742,700 thousand US$ in March 2017 to 5,835,900 thousand US$ by December 2021. While there are some fluctuations, notably downward adjustments in some quarters (e.g., December 2017 and June 2018), the overall trend reflects a strengthening equity base. This growth suggests ongoing capitalization and retained earnings accumulation, supporting a broader financial foundation for the company.
- Return on Equity (ROE)
- The ROE data, available starting from March 2018, indicates strong and generally improving profitability relative to equity. ROE values fluctuate but remain robust mostly above 17%, with peaks reaching above 28% in March and December 2020, and September 2021. This metric underscores the company's effective use of equity capital in generating profits. The temporary dip in ROE around mid-2020 aligns with the sharp net income loss in the same period, but the recovery thereafter is evident, pointing to sustained operational strength.
In summary, the company has demonstrated resilience through fluctuations in net income, including managing a significant loss period, while progressively building stockholders’ equity and maintaining strong returns on equity. The recovery and growth patterns suggest positive management of resources and potential for continued financial health, notwithstanding interim setbacks.
Return on Assets (ROA)
Edwards Lifesciences Corp., ROA calculation (quarterly data)
| Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
ROA = 100
× (Net income (loss)Q4 2021
+ Net income (loss)Q3 2021
+ Net income (loss)Q2 2021
+ Net income (loss)Q1 2021)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The net income of the company exhibits notable fluctuations over the analyzed periods. From the first quarter of 2017 through the first quarter of 2018, net income showed a general upward trend with some variability, peaking at 282,700 thousand US dollars in the second quarter of 2018 before declining sharply to 7,000 thousand US dollars by the fourth quarter of 2018. The following quarters in 2019 witnessed a recovery and consistent growth in net income, reaching a peak of 280,200 thousand US dollars at the end of the year.
However, during 2020, there was a significant decrease in net income in the second quarter, marked by a loss of 121,900 thousand US dollars, likely reflective of extraordinary conditions during that period. Despite this downturn, the company rebounded strongly in the latter quarters of 2020 and into 2021, with net income reaching its highest recorded value of 489,500 thousand US dollars in the fourth quarter of 2021, followed by a slight decrease but maintaining elevated levels throughout 2021.
Total assets demonstrated a steady and consistent growth trajectory over the entire period. Beginning at 4,780,400 thousand US dollars in the first quarter of 2017, total assets gradually increased, with minor fluctuations, culminating in 8,502,600 thousand US dollars by the end of 2021. This consistent asset growth suggests ongoing investment and expansion efforts.
Return on Assets (ROA) was not provided for the initial quarters but is available from the fourth quarter of 2017 onward. ROA values generally indicate strong profitability relative to assets, with percentages typically ranging between approximately 10% to 19%. The highest ROA was observed in the first quarter of 2021 at 19.09%, coinciding with strong net income figures during that period. There was a noticeable decline in ROA in the third quarter of 2020 to 11.58%, consistent with the net income drop experienced that quarter. Overall, ROA maintained a relatively high and stable level, signifying efficient asset utilization across most periods reported.
In summary, the company experienced overall net income growth with a significant disruption in mid-2020, likely related to external factors. Total assets continually increased, reflecting asset accumulation and potential business growth. ROA maintained high levels except during the temporary income downturn, indicating effective asset management throughout the periods analyzed.
- Net Income Trend
- Fluctuated with strong growth interrupted by a considerable loss in Q2 2020, recovering thereafter to record highs in late 2021.
- Total Assets Trend
- Consistent increase throughout the period, suggesting ongoing investment and expansion.
- Return on Assets (ROA) Trend
- Generally stable and strong, peaking in Q1 2021, with a dip corresponding to the net income loss in mid-2020.